Investigators Navigate the Complicated Treatment Landscape of Chemotherapy-Induced Neutropenia
January 19th 2022Advances in the treatment of solid tumors and hematologic malignancies have resulted in the development of thera-peutic regimens that can be administered at various points in a patient’s care.
The Future of Cancer Care Depends on Trust in the Scientific Community
January 4th 2022Maurie Markman, MD, shares how evidence strongly supports that approaches to cancer prevention have little chance of success unless those being targeted are willing to listen to, and ultimately trust, the recommendations being made by members of the scientific community.
Pembrolizumab Proves Potential as New Standard of Care for RCC in Adjuvant Setting
December 17th 2021Pembrolizumab demonstrated a statistically significant and clinically meaningful improvement in disease-free survival vs placebo as a postnephrectomy adjuvant therapy in patients with renal cell carcinoma at intermediate-high or high risk of recurrence, and in those who are M1 with no evidence of disease.